tetano
Editor, Senior Moderator
Ann Cardiol Angeiol (Paris). 2020 Apr 7. pii: S0003-3928(20)30056-1. doi: 10.1016/j.ancard.2020.04.001. [Epub ahead of print]
[COVID-19 pandemia: Impact on the cariovascular system. Data of 1[SUP]st[/SUP] April 2020].
[Article in French]
El Boussadani B[SUP]1[/SUP], Benajiba C[SUP]1[/SUP], Aajal A[SUP]1[/SUP], Ait Brik A[SUP]1[/SUP], Ammour O[SUP]1[/SUP], El Hangouch J[SUP]1[/SUP], Oussama O[SUP]1[/SUP], Oussama B[SUP]1[/SUP], Tahiri N[SUP]1[/SUP], Raissuni Z[SUP]2[/SUP].
Author information
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells with angiotensin receptors, leading to pneumonia linked to COVID-19. The virus has a double impact on the cardiovascular system, the infection will be more intense if the host has cardiovascular co-morbidities and the virus can cause life-threatening cardiovascular lesions. Therapies associated with COVID-19 may have adverse cardiovascular effects. Therefore, special attention should be given to cardiovascular protection during COVID-19 infection.
Copyright ? 2020 Elsevier Masson SAS. All rights reserved.
KEYWORDS:
COVID-19; Cardiac impact; Gestion des th?rapeutiques; Impact cardiaque; Therapeutics management
PMID:32303363DOI:10.1016/j.ancard.2020.04.001
[COVID-19 pandemia: Impact on the cariovascular system. Data of 1[SUP]st[/SUP] April 2020].
[Article in French]
El Boussadani B[SUP]1[/SUP], Benajiba C[SUP]1[/SUP], Aajal A[SUP]1[/SUP], Ait Brik A[SUP]1[/SUP], Ammour O[SUP]1[/SUP], El Hangouch J[SUP]1[/SUP], Oussama O[SUP]1[/SUP], Oussama B[SUP]1[/SUP], Tahiri N[SUP]1[/SUP], Raissuni Z[SUP]2[/SUP].
Author information
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells with angiotensin receptors, leading to pneumonia linked to COVID-19. The virus has a double impact on the cardiovascular system, the infection will be more intense if the host has cardiovascular co-morbidities and the virus can cause life-threatening cardiovascular lesions. Therapies associated with COVID-19 may have adverse cardiovascular effects. Therefore, special attention should be given to cardiovascular protection during COVID-19 infection.
Copyright ? 2020 Elsevier Masson SAS. All rights reserved.
KEYWORDS:
COVID-19; Cardiac impact; Gestion des th?rapeutiques; Impact cardiaque; Therapeutics management
PMID:32303363DOI:10.1016/j.ancard.2020.04.001